NeoGenomics Reports 17% Revenue Growth to Record $69 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
NeoGenomics (NEO) Tops Q3 EPS by 3c, Beats on Revenues; Lifts FY18 EPS/Revenue Outlook Above Consensus
October 30, 2018 7:12 AM EDTNeoGenomics (NASDAQ: NEO) reported Q3 EPS of $0.05, $0.03 better than the analyst estimate of $0.02. Revenue for the quarter came in at $69.1 million versus the consensus estimate of $66.33 million.
Douglas M. VanOort, the Companys Chairman and CEO, commented, Third quarter results were outstanding. Clinical and Pharma Services Divisions each reported record revenue. Test volume... More
